Celcuity Inc. (CELC) jumped 38.83% to $72.11, up $20.15, after announcing encouraging Phase 1 results for its investigational therapy gedatolisib in combination with Nubeqa (darolutamide) for men with metastatic castration-resistant prostate cancer (mCRPC).
Celcuity's Chief Medical Officer said the data compare favorably to existing treatments and confirmed that the company has begun enrolling patients in the updated Phase 1/1b trial to determine the recommended Phase 2 dose.
The stock opened at $70.45, reached a high of $74.20 and a low of $69.82, compared to a previous close of $51.96. It trades on the NASDAQ, with volume of 1.7 million shares versus an average volume of 0.2 million. The 52-week range is $10.84 - $76.31.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.